Anti-tumour therapeutic efficacy of OX40L in murine tumour model

Vaccine

Volumn 22, Issue 27-28, 2004, Pages 3585-3594

  Ali, Selman A ^a   Ahmad, Murrium ^a   Lynam, June ^a   McLean, Cornelia S ^b   Entwisle, Claire ^b   Loudon, Peter ^b   Choolun, Esther ^b   McArdle, Stephanie E B ^a   Li, Geng ^a   Mian, Shahid ^a   Rees, Robert C ^a  

^a NOTTINGHAM TRENT UNIVERSITY   (United Kingdom)

^b Cantab Pharmaceuticals Ltd   (United Kingdom)

Author keywords

CTL; OX40L; Vaccination

Indexed keywords

AMINO ACID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LIGAND; OX40 LIGAND; SERYLPROLYLSERYLTYROSYLVALYLTYROSYLHISTIDYLGLUTAMINYLPHENYLALANINE; THREONYLPROLYLHISTIDYLPROLYLALANYLARGINYLISOLEUCYLGLYCYLLEUCINE; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER IMMUNOTHERAPY; COLON CARCINOMA; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXIC T LYMPHOCYTE; FEMALE; GENETIC CODE; HERPES SIMPLEX VIRUS; HUMAN; METASTASIS INHIBITION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SPLEEN CELL; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE ACTIVATION; TUMOR REJECTION; VACCINATION;

EID: 4143106890     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2004.03.041     Document Type: Article

References (35)

1. Bretscher P. The two-signal model of lymphocyte activation twenty-one years later. Immunol. Today. 13:1992;74-76
2. Carreno B.M., Collins M. The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu. Rev. Immunol. 20:2002;29-53
3. Guinan E.C., Gribben J.G., Boussiotis V.A. Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumour immunity. Blood. 84:1994;3261-3282
4. Hellstrom K.E., Chen L., Hellstrom I. Costimulation of T-cell-mediated tumour immunity. Cancer Chemother Pharmacol. 38(Suppl):1996;S40-S41
5. Croft M., Joseph S.B., Miner K.T. Partial activation of naive CD4 T cells and tolerance induction in response to peptide presented by resting B cells. J. Immunol. 159:1997;3257-3265
6. Oh S., Hodge J.W., Ahlers J.D., Burke D.S., Schlom J., Berzofsky J.A. Selective induction of high avidity CTL by altering the balance of signals from APC. J Immunol. 170:2003;2523-2530
7. Murtaza A., Kuchroo V.K., Freeman G.J. Changes in the strength of co-stimulation through the B7/CD28 pathway alter functional T cell responses to altered peptide ligands. Int Immunol. 11:1999;407-416
8. Bansal-Pakala P, Jember AG, Croft M. Signaling through OX40 (CD134) breaks peripheral T-cell tolerance. Nat Med 2001;(8):907-12.
9. Smith C.A., Farrah T., Goodwin R.G. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell. 76:1994;959-962
10. Gruss H.J., Dower S.K. Tumour necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas. Blood. 85:1995;3378-3404
11. Weinberg A.D., Rivera M.M., Prell R., et al. Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J Immunol. 164:2000;2160-2169
12. Stuber E., Neurath M., Calderhead D., et al. Cross-linking of OX40 ligand, a member of the TNF/NGF cytokine family, induces proliferation and differentiation in murine splenic B cells. Immunity. 2:1995;507-521
13. Imura A., Hori T., Imada K., et al. The human OX40/gp34 system directly mediates adhesion of activated T cells to vascular endothelial cells. J Exp Med. 183:1996;2185-2195
14. Gramaglia I., Weinberg A.D., Lemon M., Croft M. Ox-40 ligand: a costimulatory molecule for sustaining primary CD4 T cell responses. J. Immunol. 161:1998;6510-6517
15. Maxwell J.R., Weinberg A.D., Prell R., Vell A.T. Danger and OX40 receptor signaling synergize to enhance memory T cell survival by inhibiting peripheral deletion. J Immunol. 164:2000;107-112
16. Gramaglia I., Jember A., Pippig S.D., Weinberg A.D., Killeen N., Croft M. The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion. J. Immunol. 165:2000;3043-3050
17. Akiba H., Miyahira Y., Atsuta M., Takeda K., Nohara C., Futagawa T., et al. Critical contribution of OX40 ligand to T helper cell type 2 differentiation in experimental leishmaniasis. J Exp Med. 191:2000;375-380
18. Kjaergaard J., Tanaka J., Kim J.A., Rothchild K., Weinburg A.D., Shu S. Therapeutic efficacy of OX-40 receptor antibody depends on tumour immunogenicity and anatomic site of tumour growth. Cancer Res. 60:2000;5514-5521
19. Vetto J.T., Lum S., Morris A., Sicotte M., Davies J., Lemon M., et al. Presence of the T-cell activation marker OX-40 on tumour infiltrating lymphocytes and draining lymph node cells from patients with melanoma and head and neck cancers. Am J Surg. 174:1997;258-265
20. Ali S.A., McLean C.S., Boursnell M., Martin G., Holmes C.L., Reeder S., et al. The pre-clinical evaluation of whole cell vaccines for prophylaxis and therapy: the use of DISC HSV vector to transduce cytokine genes. Cancer Res. 60:2000;1663-1670
21. Todryk S., McLean C.S., Ali S.A., Entwisle C., Boursnell M., Rees R., et al. Disabled infectious single cycle herpes simplex virus vector for immunotherapy of colorectal cancer. Hum Gene Ther. 10:1999;2757-2768
22. Whittle N., Adair J., Lloyd C., Jenkins L., Devine J., Scholm J., et al. Expression in COS cells of a mouse-human chimaeric B72.3 antibody. Protein Eng. 1:1987;499-505
23. Pan P.Y., Zang Y., Weber K., Meseck M.L., Chen S.H. OX40 ligation enhances primary and memory cytotoxic T lymphocyte responses in an immunotherapy for hepatic colon metastases. Mol Ther. 6:2002;528-536
24. Morris A., Vetto J.T., Ramstad T., Funatake C.J., Choolun E., Entwisle C., et al. Induction of anti-mammary cancer immunity by engaging the OX-40 receptor in vivo. Breast Cancer Res Treat. 67:2001;71-80
25. Stuber E., Strober W. The T cell-B cell interaction via OX40-OX40L is necessary for the T cell-dependent humoral immune response. J Exp Med. 183:1996;979-989
26. Ali S.A., Lynam J., McLean C.S., Entwisle C., Loudon P., Rojas J.M. Tumour regression induced by intratumor therapy with a disabled infectious single cycle (DISC) herpes simplex virus (HSV) vector, DISC/HSV/murine granulocyte-macrophage colony-stimulating factor, correlates with antigen-specific adaptive immunity. J Immunol. 168:2002;3512-3519
27. Rogers P.R., Song J., Gramaglia I., Killeen N., Croft N. OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells. Immunity. 15:2001;445-455
28. Weinberg A.D., Bourdette D.N., Sullivan T.J., Lemon M., Wallin J.J., Maziarz R., et al. Selective depletion of myelin-reactive T cells with the anti-OX-40 antibody ameliorates autoimmune encephalomyelitis. Nat Med. 2:1996;183-189
29. Weinberg A.D. Antibodies to OX-40 (CD134) can identify and eliminate autoreactive T cells: implications for human autoimmune disease. Mol Med Today. 4:1998;76-83
30. Petty J.K., He K., Coreless C.L., Vetto J.T., Weinberg A.D. Survival in human colorectal cancer correlates with expression of the T-cell costimulatory molecule OX-40 (CD134). Am J Surg. 183:2002;512-518
31. Weinberg A.D. OX40: targeted immunotherapy - implications for tempering autoimmunity and enhancing vaccines. Trends Immunol. 23:2002;102-109
32. Murata K, Nose M, Ndhlova LC, Sato T, Sugamura K, Ishii N. Constitutive OX40/OX40 Ligand interaction induces autoimmune-like diseases. J Immunol 169:4628-36.
33. Kashii Y., Giorda R., Herbermann R.B., Whiteside T.L., Vujanovic N.L. Constitutive expression and role of the TNF family ligands in apoptotic killing of tumour cells by human NK cells. J. Immunol. 163(10):1999;5358-5366
34. Wang H.C., Klein J.R. Multiple levels of activation of murine CD8(+) intraepithelial lymphocytes defined by OX40 (CD134) expression: effects on cell-mediated cytotoxicity, IFN-gamma, and IL-10 regulation. J. Immunol. 167:2001;6717-6723
35. Kjaergaard J., Peng L., Cohen P.A., Drazba J.A., Weinberg A.D., Shu S. Augmentation versus inhibition: effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumour. J. Immunol. 67:2001;6669-6677